Evidence map›Paper›PMID 32123156›Full record

ArticleTranslational psychiatry2020

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease.

Balmiki Ray, Bryan Maloney, Kumar Sambamurti, Hanuma K Karnati, Peter T Nelson, Nigel H Greig, Debomoy K Lahiri

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Balmiki RayDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Bryan MaloneyDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.ORCID http://orcid.org/0000-0003-2364-9649
Kumar SambamurtiDepartment of Neurosciences, Medical University of South Carolina, Charleston, 29425 SC, USA.
Hanuma K KarnatiNational Institute on Aging, Drug Design and Development Section, Bethesda, MD, 20892, USA.
Peter T NelsonSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536, USA.
Nigel H GreigNational Institute on Aging, Drug Design and Development Section, Bethesda, MD, 20892, USA.
Debomoy K LahiriDepartment of Psychiatry, Laboratory of Molecular Neurogenetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. dlahiri@iupui.edu.ORCID http://orcid.org/0000-0002-1664-5933
Indiana University School of MedicineNational Institute on Aging · USMedical University of South Carolina · USUniversity of Kentucky · US

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI WILCOCK, DONNA M · 2006 to 2020
$23.3M
NIA NIH HHS P30 AG028383NIA NIH HHS P30 AG072946
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32123156
PMCPMC7052148
OpenAlexW3009795118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.